A PHP Error was encountered
Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_session5rk13nu65p8lvnth05igpqkpdhhokg39): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
A PHP Error was encountered
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case-control analysis, in primary care.
Intern Emerg Med
Italian College of General Practitioners and Primary Care, Florence, Italy.
Published: November 2022
Background And Objective: This study aimed to compare the prescribing patterns of paracetamol in COVID-19 with those for similar respiratory conditions and investigated the association between paracetamol use and COVID-19-related hospitalization/death.
Methods: Using a primary care data source, we conducted a cohort study to calculate the incidence rate of paracetamol use in COVID-19 and for similar respiratory conditions in 2020 and 2019 (i.e. pre-pandemic phase), respectively. In the study cohort, we nested a case-control analyses to investigate the association between paracetamol use and COVID-19-related hospitalizations/deaths.
Results: Overall, 1554 (33.4 per 1000) and 2566 patients (78.3 per 1000) were newly prescribed with paracetamol to treat COVID-19 or other respiratory conditions, respectively. Those aged 35-44 showed the highest prevalence rate (44.7 or 99.0 per 1000), while the oldest category reported the lowest value (17.8 or 39.8 per 1000). There was no association for early (OR = 1.15; 95% CI: 0.92-1.43) or mid-term (OR = 1.29; 95% CI: 0.61-2.73) users of paracetamol vs. non-users. Instead, the late users of paracetamol showed a statistically significant increased risk of hospitalization/death (OR = 1.75; 95% CI: 1.4-2.2).
Conclusions: Our findings provide reassuring evidence on the use and safety profile of paracetamol to treat early symptoms of COVID-19 as in other respiratory infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362076 | PMC |
| http://dx.doi.org/10.1007/s11739-022-03054-1 | DOI Listing |
Similar Publications
Comparative analysis of croup severity and treatment in pediatric patient: a study of COVID-19 positive vs. negative cases during peak Omicron.
BMC Pediatr
March 2025
Emergency devision, school of medicine, Bahrami hospital, Tehran University of Medical Science, Tehran, Iran.
Background: The Omicron variant of SARS-CoV-2 has been associated with unique clinical presentations in children, including croup-like symptoms such as barking cough, hoarseness, and respiratory distress. This study aimed to compare the clinical, laboratory, and treatment characteristics of hospitalized pediatric patients with croup who tested positive or negative for COVID-19 during the Omicron wave.
Methods: A retrospective, descriptive-analytical study was conducted on 111 pediatric patients hospitalized with croup at Bahrami Children's Hospital and the Children's Medical Center in Iran from January 21 to March 20, 2022.
Risk prediction and early intervention strategies for persistent SARS-CoV-2 infection in patients with non-Hodgkin lymphoma: a retrospective cohort study.
BMC Pulm Med
March 2025
Department of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Background: Patients with non-Hodgkin lymphoma (NHL) face heightened mortality and accelerated disease progression when persistently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This critical situation underscores the urgent need to identify risk factors and establish early intervention strategies tailored to this vulnerable population. The primary aim of this study was to investigate the risk factors associated with persistent SARS-CoV-2 infection in NHL patients during the COVID-19 pandemic.
View Article and Find Full Text PDFAntibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023-February 2024.
BMC Infect Dis
March 2025
Scientific Research Institute for Systems Biology and Medicine, Federal Service on Consumer Rights Protection and Human Well-Being Surveillance, Moscow, Russia.
Background: Mycoplasma pneumoniae (MP) is a common bacterial respiratory infection that can cause pneumonia, particularly in children. Previously published data have highlighted the high incidence of viral co-infections and the problem of increasing macrolide resistance in MP worldwide.
Aims: (1) to estimate the impact of viral infections circulating in a local population on the spectrum of co-infection in hospitalized children with Mycoplasma pneumoniae pneumonia (MPP), (2) to determine if there are differences in resistance mutation rate for samples from hospitals of Russia located in the European and Far East, (3) to describe genomic characteristics of MP from Russian patients during the MPP outbreaks in the fall-winter of 2023-2024.
Severe Acute Respiratory Syndrome Coronavirus 2 Immunology and Coronavirus Disease 2019 Clinical Outcomes.
Infect Dis Clin North Am
March 2025
Ragon Institute of MGB, MIT and Harvard, 600 Main Street, Cambridge, MA 02139; Division of Gastroenterology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02115. Electronic address:
The humoral and cellular immune response are the key players in preventing viral infection and limiting disease severity, particular in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019. In this review, we discuss how immune responses generated by prior infection and vaccination influence the outcomes of SARS-CoV-2 infection. We aim to provide an overview of the role of humoral and cellular immunity, with a particular focus on CD8 T cell responses, to delineate how different immune compartments contribute to the control of infection and modulation of disease outcomes.
View Article and Find Full Text PDFRecent trends in hospitalizations for Respiratory Syncytial Virus after the COVID-19 pandemic and before routine immunization: seasonality and severity updates from the 2023/2024 season in Tuscany, Italy.
Int J Infect Dis
March 2025
Epidemiologic Observatory, Regional Healthcare Agency of Tuscany, Firenze, Italy.
Background: RSV epidemiology was disrupted by the COVID-19 pandemic. This study investigates the 2023/2024 RSV season in Tuscany, Italy, to assess trends in seasonality and incidence of RSV-associated hospitalizations compared to pre-pandemic and prior post-pandemic seasons.
Methods: We analyzed RSV-associated hospitalizations in Tuscany during the 2023/2024 season, just before the implementation of routine immunization with nirsevimab, with a dynamic cohort consisting of all resident children aged ≤2 years, using regional registries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.